Biography
Publications and Further Research Outputs
Peer-Reviewed Publications
Malebari, AM, Greene, LM, Nathwani, SM, Fayne, D, O'Boyle, NM, Wang, S, Twamley, B, Zisterer, DM, Meegan, MJ, β-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells, European Journal of Medicinal Chemistry, 130, 2017, p261-285
O'Boyle, NM, Barrett, I, Greene, LM, Carr, M, Fayne, D, Twamley, B, Knox, AJS, Keely, NO, Zisterer, DM, Meegan, MJ, Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity, Journal of Medicinal Chemistry, 2017
Meegan MJ, Nathwani S, Twamley B, Zisterer DM, O'Boyle NM., Piperlongumine (piplartine) and analogues: Antiproliferative microtubule-destabilising agents., European Journal of Medicinal Chemistry, 125, 2017, p453 - 463
Greene TF, Wang S, Greene LM, Nathwani SM, Pollock JK, Malebari AM, McCabe T, Twamley B, O'Boyle NM, Zisterer DM, Meegan MJ, Synthesis and Biochemical Evaluation of 3-Phenoxy-1,4-diarylazetidin-2-ones as Tubulin-Targeting Antitumor Agents., Journal of Medicinal Chemistry, 59, (1), 2016, p90 - 113
O'Boyle, NM, Pollock, JK, Carr, M, Knox, AJS, Nathwani, SM, Wang, S, Caboni, L, Zisterer, DM, Meegan, MJ, β-Lactam Estrogen Receptor Antagonists and a Dual-Targeting Estrogen Receptor/Tubulin Ligand, Journal of Medicinal Chemistry, 57, (22), 2014, p9370 - 9382
Pollock, J. K. Verma, N. K. O'Boyle, N. M. Carr, M. Meegan, M. J. Zisterer, D. M., Combretastatin (CA)-4 and its novel analogue CA-432 impair T-cell migration through the Rho/ROCK signalling pathway, Biochemical pharmacology, 92, (4), 2014, p544-557
McNamara, Y. M. Bright, S. A. Byrne, A. J. Cloonan, Suzanne M. McCabe, T. Williams, D. C. Meegan, M. J., Synthesis and antiproliferative action of a novel series of maprotiline analogues, European Journal of Medicinal Chemistry, 2014
O'Boyle, N. M. Pollock, J. K. Carr, M. Knox, A. J. Nathwani, S. M. Wang, S. Caboni, L. Zisterer, D. M. Meegan, M. J., beta-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor/tubulin ligand, Journal of Medicinal Chemistry , 57, (22), 2014, p9370-82
Pollock, JK, Verma,NK, O'Boyle, NM, Carr, MG, Meegan, MJ, Zisterer, DM, Combretastatin (CA)-4 and its novel analogue CA-432 impair T-cell migration through the Rho/ROCK signalling pathway, Biochemical Pharmacology, 92, (4), 2014, p544-557
Greene, LM, Wang, S, O'Boyle, NM, Bright, SA, Reid, JEA, Kelly, PJ, Meegan, MJ, Zisterer, DM, Combretazet-3 a novel synthetic cis-stable combretastatin A-4-azetidinone hybrid with enhanced stability and therapeutic efficacy in colon cancer, Oncology Reports, 29, (6), 2013, p2451-2458
O'Boyle, N. M., Greene, L. M., Keely, N. O., Wang, S., Cotter, T. S., Zisterer, D. M., Meegan, M. J., Synthesis and biochemical activities of antiproliferative amino acid and phosphate derivatives of microtubule-disrupting beta-lactam combretastatins: , Eur J Med Chem., 62, 2013, p705 - 721
Greene, L. M., Wang, S., O'Boyle, N. M., Bright, S. A., Reid, J. E., Kelly, P., Meegan, M. J., Zisterer, D. M., Combretazet-3 a novel synthetic cis-stable combretastatin A-4-azetidinone hybrid with enhanced stability and therapeutic efficacy in colon cancer,, Oncol Rep, 29, (6), 2013, p2451 - 2458
Caboni L, Egan B, Kelly B, Blanco F, Fayne D, Meegan MJ, Lloyd DG, Structure-activity relationships in non-ligand binding pocket (non-LBP) diarylhydrazide antiandrogens., Journal of chemical information and modeling, 53, (8), 2013, p2116-30
Nathwani, S. M., Hughes, L., Greene, L. M., Carr, M., O'Boyle, N. M., McDonnell, S., Meegan, M. J., Zisterer, D. M., Novel cis-restricted beta-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro,, Oncol Rep, 29, (2), 2013, p585 - 594
Caboni, L. Egan, B., Kelly, B.,Blanco, F., Fayne, D., Meegan, M. J., Lloyd, D. G, Structure-Activity Relationships in Non-Ligand Binding Pocket (Non-LBP) Diarylhydrazide Antiandrogens,, J Chem Inf Model, 53, (8), 2013, p2116 - 2130
Greene, L. M., O'Boyle, N. M., Nolan, D. P., Meegan, M. J., Zisterer, D. M., The vascular targeting agent Combretastatin-A4 directly induces autophagy in adenocarcinoma-derived colon cancer cells, Biochem Pharmacol, 84, (5), 2012, p612 - 624
Blanco, F., Egan, B., Caboni, L., Elguero, J. O'Brien, J., McCabe, T., Fayne, D., Meegan, M. J., Lloyd, D. G, Study of E/Z isomerization in a series of novel non-ligand binding pocket androgen receptor antagonists, J Chem Inf Model, 52, (9), 2012, p2387 - 2397
Greene, LM, O'Boyle, NM, Nolan, DP, Meegan, MJ, Zisterer, DM, The vascular targeting agent Combretastatin-A4 directly induces autophagy in adenocarcinoma-derived colon cancer cells, Biochemical Pharmacology, 84, (5), 2012, p612-624
Caboni, L., Kinsella, G. K., Blanco, F., Fayne, D., Jagoe, W. N., Carr, M., Williams, D. C., Meegan, M. J., Lloyd, D. G., "True" Antiandrogens-Selective Non-Ligand-Binding Pocket Disruptors of Androgen Receptor-Coactivator Interactions: Novel Tools for Prostate Cancer, , J Med Chem,, 55, (4 ), 2012, p1635 - 1644
Keely, Niall O.; Zisterer, Daniela M.; Meegan, Mary J., Design, synthesis and biochemical evaluation of estrogen receptor ligand conjugates as tumour targeting agents , Letters in Drug Design & Discovery, 9, (3), 2012, p295 - 304
Orlagh M. Kelly, Yvonne M. McNamara, Lars H. Manzke, Mary J. Meegan, Richard K. Porter, The Preservation of in vivo Phosphorylated and Activated Uncoupling Protein 3 (UCP3) in Isolated Skeletal Muscle Mitochondria following Administration of 3,4-Methylenedioxymethamphetamine (MDMA aka Ecstasy) to Rats/Mice, Mitochondrion, 12, (1), 2012, p110-9
Yvonne M. McNamara, Suzanne M. Cloonan, Andrew J.S. Knox, John J. Keating, Stephen G. Butler, Günther H. Peters, Mary J. Meegan and D. Clive Williams, Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents, Bioorganic & Medicinal Chemistry, 19, (3), 2011, p1328 - 1348
Lisa M. Greene, Miriam Carr, Niall O. Keeley, Mark Lawler, Mary J. Meegan and Daniela M. Zisterer;, BubR1 is required for the mitotic block induced bycombretastatin-A4 and a novel cis-restricted ß-lactam analogue in human cancer cells;, International Journal of Molecular Medicine, 27, (5), 2011, p715 - 723
O'Boyle, NM, Greene, LM, Bergin, O, Fichet, JB, McCabe, T, Lloyd, DG, Zisterer, DM, Meegan, MJ, Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones, Bioorganic & Medicinal Chemistry, 19, (7), 2011, p2306-2325
Lisa M. Greene, Miriam Carr, Niall O. Keeley, Mark Lawler, Mary J. Meegan and Daniela M. Zisterer;, BubR1 is required for the mitotic block induced bycombretastatin-A4 and a novel cis-restricted ß-lactam analogue in human cancer cells;, International Journal of Molecular Medicine, 27, (5), 2011, p715 - 723
O'Boyle, NM, Meegan, MJ, Designed multiple ligands for cancer therapy, Current Medicinal Chemistry, 18, (31), 2011, p4722-4737
O'Boyle, NM, Carr, M, Greene, LM, Keely, NO, Knox, AJS, McCabe, T, Lloyd, DG, Zisterer, DM, Meegan, MJ, Synthesis, Biochemical and Molecular Modelling Studies of Antiproliferative Azetidinones causing Microtubule Disruption and Mitotic Catastrophe, European Journal of Medicinal Chemistry, 46, (9), 2011, p4595 - 4607
O'Boyle, N.M., Knox, A.J.S., Price, T.P., Williams, D.C., Zisterer, D.M., Lloyd, D.G., Meegan, M.J.,, Lead identification of beta-lactam and related imine inhibitors of the molecular chaperone heat shock protein 90, Bioorganic & Medicinal Chemistry, 19, (20), 2011, p6055-6068
Miriam Carr, Lisa M. Greene, Andrew J.S. Knox, David G Lloyd, Daniela M. Zisterer and Mary J. Meegan, Lead identification of conformationally restricted β-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects, European Journal of Medicinal Chemistry, 45, (12), 2010, p5752-5766
Greene LM, Nathwani SM, Bright SA, Fayne D, Croke A, Gargliardi M, Mc Elligott AM, O'Connor L, Carr M, Keely NO, O'Boyle NM, Carroll P, Sarkadi B, Conneally E, Lloyd DG, Lawler M, Meegan MJ, Zisterer DM, The vascular targeting agent Combretastatin-A4 and a novel cis-restricted {beta}-lactam analogue CA-432 induce apoptosis in human chronic myeloid leukemia cells and in ex vivo patient samples including those displaying multidrug resistance., The Journal of Pharmacology and Experimental Therapeutics, 335, (2), 2010, p302 - 313
Yang Y, Carta G, Peters MB, Price T, O'Boyle N, Knox AJ, Fayne D, Williams DC, Meegan MJ, Lloyd DG , 'tieredScreen' - Layered Virtual Screening Tool for the Identification of Novel Estrogen Receptor Alpha, Molecular Informatics, 29, 2010, p421 - 430
Barrett I, Carr M, O'Boyle N, Greene LM, Knox AJ, Lloyd DG, Zisterer DM, Meegan MJ, Lead identification of conformationally restricted benzoxepin type combretastatin analogs: synthesis, antiproliferative activity, and tubulin effects., Journal of enzyme inhibition and medicinal chemistry, 25, (2), 2010, p180-94
Suzanne M. Cloonan, John J. Keating, John E. O'Brien, Desmond Corrigan, Pierce V Kavanagh, D. Clive Williams and Mary J. Meegan, Synthesis and in vitro toxicity of 4-MTA, its characteristic clandestine synthesis byproducts and related sulphur substituted á-alkylthioamphetamines, Bioorganic and Medicinal Chemistry, 18, 2010, p4009 - 4031
Nathwani, S-M., Butler, S., Meegan, M.J., Campiani, G., Lawler, M., Williams, D.C. & Zisterer, D.M., Dual targeting of tumour cells and host endothelial cells by novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines., Cancer Chemotherapy and Pharmacology, 65, (2), 2010, p289-300
O'Boyle NM, Carr M, Greene LM, Bergin O, Nathwani SM, McCabe T, Lloyd DG, Zisterer DM, Meegan MJ, Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents, Journal of Medicinal Chemistry, 53, (24), 2010, p8569-8584
Suzanne M. Cloonan, John J. Keating, Stephen G. Butler, Andrew J.S. Knox, Anne M. Jørgensen, Günther H. Peters, Dilip Rai,Desmond Corrigan, David G. Lloyd, D. Clive Williams and Mary J. Meegan, Synthesis and serotonin transporter activity of sulphur-substituted á-alkyl phenethylamines as a new class of anticancer agents, European Journal of Medicinal Chemistry, 44, (12), 2009, p4862 - 4888
Bright S.A., Greene, L.M., Greene, T.F., Campiani, G., Buitini, S., Brindisi, M., Lawler, M., Meegan, M.J., Williams, D.C. and Zisterer, D.M. , The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells, Biochemical Pharmacology, 77, (3), 2009, p310-321
Knox, AJS; Yang, YD; Lloyd, DG; Meegan, MJ, Virtual screening of the estrogen receptor , EXPERT OPINION ON DRUG DISCOVERY , 3, (8), 2008, p853-866
Butler, S. G., Meegan, M. J., , Recent developments in the design of anti-depressive therapies: targeting the serotonin transporter, Curr Med Chem, 15 , (17), 2008, p1737-6-
Barrett, I., Meegan, M.J., Hughes, R.B., Carr, M., Knox, A.J.S. Artemenko, N., Golfis, G., Zisterer, D.M. & Lloyd, D.G., Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators., Bioorganic & Medicinal Chemistry, 16, (21), 2008, p9554-9973
Knox AJS, Yang YD, Lloyd DG, Meegan, MJ, Virtual screening of the estrogen receptor, Expert opinion on drug discovery, 3, (8), 2008, p853 - 866
Meegan, M.J., Carr, M., Knox, A.J.S., Zisterer, D.M. & Lloyd, D.G., Beta-Lactam type molecular scaffolds for antiproliferative activity: Synthesis and cytotoxic effects in breast cancer cells., Journal of Enzyme Inhibition and Medicinal Chemistry, 23, (5), 2008, p668-685
Bright, S. A.,Greene, L. M.,Greene, T. F.,Campiani, G.,Butini, S.,Brindisi, M., Lawler, M., Meegan, M. J., Williams, D. C., Zisterer, D. M.;, The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells, Biochem Pharmacol, 2008, October 30, 2008
Barrett, I., Meegan, M. J.,Hughes, R. B., Carr, M., Knox, A. J., Artemenko, N., Golfis, G., Zisterer, D. M., Lloyd, D. G.,, Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators, Bioorg Med Chem; , 16, (21), 2008, p9554-73-
Meegan, M. J., Carr, M., Knox, A. J., Zisterer, D. M., Lloyd, D. G., , Beta-lactam type molecular scaffolds for antiproliferative activity: synthesis and cytotoxic effects in breast cancer cells, J Enzyme Inhib Med Chem, 23, , (5), 2008, p668-85-
Andrew J. S. Knox, Mary J. Meegan, Vladimir Sobolev, Dermot Frost, Daniela M. Zisterer, D. Clive Williams, and David G. Lloyd, , 5. Target Specific Virtual Screening: Optimization of an Estrogen Receptor Screening Platform, Journal of Medicinal Chemistry, , 50, (22), 2007, p5301-10-
Meegan, M.J., Barrett, I., Zimmmermann, J., Knox, A.J.S., Zisterer, D.M. & Lloyd, D.G. , Benzothiepin-derived molecular scaffolds for estrogen receptor modulators: synthesis and antagonistic effects in breast cancer cells. , Journal of Enzyme Inhibition and Medicinal Chemistry, 22, (5), 2007, p655-66
Mary J Meegan, Irene Barrett, Jochen Zimmermann, Andrew J.S.Knox, Daniela M Zisterer, and David G Lloyd; , 6. Benzothiepin derived molecular scaffolds for estrogen eceptor modulators: synthesis and antagonistic effects in breast cancer cells, Journal of Enzyme Inhibition and Medicinal Chemistry, 22 , (5), 2007, p655-666.-
David G. Lloyd, Helena M. Smith, Andrew S. Knox, Daniela M. Zisterer and Mary J. Meegan, , 1. Flexible Estrogen Receptor Modulators: Synthesis, Biochemistry and Molecular Modeling Studies for 3-Benzyl-4,6-diarylhex-3-ene and 3,4,6-Triarylhex-3-ene Derivatives; , Medicinal Chemistry, 3, 2007, p135 - 155
Smith, H.M., Knox, A.S., Zisterer, D.M., Lloyd, D.G., & Meegan, M.J. , Flexible estrogen receptor modulators: synthesis, biochemistry and molecular modeling studies for 3-benzyl-4,6-diarylhex-3-ene and 3,4,6-triarylhex-3-ene derivatives., Medicinal Chemistry, 3, (2), 2007, p135 - 155
Knox AJ, Meegan MJ, Sobolev V, Frost D, Zisterer DM, Williams DC, Lloyd DG., Target specific virtual screening: optimization of an estrogen receptor screening platform., Journal of Medicinal Chemistry, 50, (22), 2007, p5301-5310
David G. Lloyd, Georgia Golfis, Andrew J.S. Knox, Darren Fayne, Mary J. Meegan and Tudor I. Oprea, Oncology Exploration : Charting Cancer Medicinal Chemistry Space , Drug Discovery Today, 11, (3/4), 2006, p149 - 159
Meegan, M.J., , Nuclear Receptors as targets in Drug Discovery: Medicinal and Therapeutic Potential; , Current Topics in Medicinal Chemistry, , 6, , , (3), 2006, p179-
David G. Lloyd, Helena M. Smith, Timothy O'Sullivan, Andrew S. Knox,, Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes : Synthesis, Structure-Activity Relationships and Molecular Modeling Study for Flexible Estrogen Receptor Antagonists;, Medicinal Chemistry, 2, (2), 2006, p147 - 168
Andrew J S Knox, Mary J Meegan and David G Lloyd, Estrogen Receptors; Molecular Interactions, Virtual screening and Future Prospects, Current Topics in Medicinal Chemistry, 6, (2), 2006, p211 - 237
Lloyd, D.G., Smith, H.M., O'Sullivan, T., Knox, A.S., Zisterer, D.M. & Meegan, M.J. , Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes : Synthesis, Structure-Activity Relationships and Molecular Modeling Study for Flexible Estrogen Receptor Antagonists , Medicinal Chemistry, 2, (2), 2006, p147 - 168
Knox AJS, Meegan MJ, Lloyd DG, Estrogen Receptor: Molecular Interactions, Virtual Screening and Future Prospects., Current Topics in Medicinal Chemistry, 6, (3), 2006, p217 - 243
Knox AS, Meegan MJ, Carta G, Lloyd DG, Considerations in Compound Database Preparations Hidden Impact on Virtual Screening Results, Journal of Chemical Information and Modelling, 45, (6), 2005, p1908 - 1919
Understanding the molecular mechanism of estrogen receptor modulators in, editor(s)Atta-ur-Rhaman, Reitz A B , Frontiers in Medicinal Chemistry, Bentham Science Publishers, 2005, pp183 - 231, [David G. Lloyd, Mary J. Meegan]
Lloyd DG, Smith HM, O'Sullivan T, Zisterer DM, Meegan MJ, Synthesis, Structure-Activity Relationships and Antagonistic Effects in Human MCF-7 Breast Cancer Cells of Flexible Estrogen Receptor Modulators, Medicinal Chemistry, 1, (4), 2005, p335 - 353
David G. Lloyd, Helena M. Smith, Timothy O'Sullivan, Daniela M. Zisterer , Synthesis, Structure-Activity Relationships and Antagonistic Effects in Human MCF-7 Breast Cancer Cells of Flexible Estrogen Receptor Modulators, Medicinal Chemistry, 1, (4), 2005, p335 - 353
David G. Lloyd, Rosario B. Hughes, Daniela M. Zisterer, D. Clive Williams, Caterina Fattorusso, Bruno Catalanotti, Giuseppe Campiani, Mary J. Meegan, Benzoxepin derived estrogen receptor modulators: A novel molecular scaffold for the estrogen receptor, Journal of Medicinal Chemistry, 47, 2004, p5612
Lloyd DG, Hughes RB, Zisterer DM, Williams DC, Fattorusso C, Catalanotti B, Campiani G, Meegan MJ., Benzoxepin-derived estrogen receptor modulators: a novel molecular scaffold for the estrogen receptor, Journal of Medicinal Chemistry, 47, (23), 2004, p5612 - 5615
MJ Meegan and DG Lloyd, Advances in the Science of Estrogen Receptor Modulation, Current Medicinal Chemistry, 10, 2003, p181 - 210
M.J. Meegan, R.B. Hughes, D.G. Lloyd, D.C. Williams and D.M. Zisterer., Anti-Cancer Drug Design,, Ethyl side chain modifications in novel flexible antiestrogens - design, synthesis and biological efficacy in essay against the MCF-7 breast tumor cell line, 16, 2001, p57 - 69
Meegan, M., Hughes, R., Lloyd, D.G., Zisterer, D.M. & Williams, D.C. , Flexible estrogen receptor modulators: design, synthesis and antagonistic effects in human MCF-7 breast cancer cells. , Journal Medicinal Chemistry, 44, (7), 2001, p1072 - 1084
A.D. Neary, C.M. Burke, A.C. O'Leary and Mary J. Meegan, Transformation of 4-acetoxy-3-vinylazetidin-2-ones to 3-(1-hydroxyethyl)azetidin-2-ones and 3-ethylideneazetidin2-onens: intermediates for carbapenem antibiotics. , Journal of Chemical Research,(M), 2001, p501 - 522
A.D. Neary, C.M. Burke, A.C. O'Leary and Mary J. Meegan. , Transformation of 4-acetoxy-3-vinylazetidin-2-ones to 3-(1-hydroxyethyl)azetidin-2-ones and 3-ethylideneazetidin2-onens: intermediates for carbapenem antibiotics. , Journal of Chemical Research, (S) , 2001, p166 - 169
M.J. Meegan, R.B. Hughes, D.G. Lloyd, D.C. Williams and D.M. Zisterer,, 'Flexible estrogen receptor modulators - design, synthesis and antagonistic effects in human MCF-7 breast cancer cells', Journal of Medicinal Chemistry, 44, (7), 2001, p1072 - 1084
P. Kavanagh, J. Dunne, J. Feely, R. Maguire, D. Corrigan, J.J. Keating, M.J. Meegan, J.M. Clancy and J. Burdett, 47. Prenylalkylamine abuse among opiate addicts attending a methadone treatment programme in the Republic of Ireland, Addiction Biology, 7, 2001, p177 - 181
Meegan MJ, Hughes RB, Lloyd DG, Williams DC, Zisterer DM, Ethyl side-chain modifications in novel flexible antiestrogens--design, synthesis and biological efficacy in assay against the MCF-7 breast tumor cell line, Anticancer Drug Design , 16, (1), 2001, p57 - 69
D.G. Lloyd and M.J. Meegan, 45. 'Recent advances in estrogen receptor antagonists' , I Drugs , 3, (6), 2000, p632 - 642
Lloyd DG, Meegan MJ , Recent advances in estrogen receptor antagonists , IDrugs , 3, (6), 2000, p632 - 642
P.V. Kavanagh, D. Corrigan, R.T. Maguire, M.J. Meegan, J.J. Keating, J. Clancy and J. Burdett, . Excretion profile of 4-Methylthioamphetamine in Dogs, Pharmacy and Pharmacology Communications., , 5, 1999, p653 - 655
A.C. O'Leary, C.M. Waldron, C.M. Burke, R.D. Keaveny and M.J. Meegan., 3-(2-Alkoxy-1-hydroxyethyl)azetidin-2-ones: potential intermediates for the synthesis of novel carbapenems, , Journal of Chemical Research(S) , 1998, p64 - 65
A.C. O'Leary, C.M. Waldron, C.M. Burke, R.D. Keaveny and M.J. Meegan., 3-(2-Alkoxy-1-hydroxyethyl)azetidin-2-ones: potential intermediates for the synthesis of novel carbapenems, Journal of Chemical Research(M) , 1998, p434 - 456
T.A. Nakib, P. Perjesi, R. Varghese and M.J. Meegan., Benzlideneindanones and benzylidenebenzosuberones: relationship of structure, antimcotic activity and acute toxicity, Medical Principles Practice, 6, 1997, p12 - 21
M.J. Meegan, C.M. Waldron, R.D. Keaveny and A.D. Neary, 4-Acetoxy-3-[1-(2-arylamino-1-hydroxy)ethyl]azetidin-2-ones: intermediates for the synthesis of novel carbapenems(S), Journal of Chemical Research , 1997, p158 - 159
. M.J. Meegan, C.M. Waldron, R.D. Keaveny and A.D. Neary., 4-Acetoxy-3-[1-(2-arylamino-1-hydroxy)ethyl]azetidin-2-ones: intermediates for the synthesis of novel carbapenems, , Journal of Chemical Research (M), 1997, p1101 - 1126
Fiona M. Murphy and Mary J. Meegan, A New Synthesis of the 1,4-Dihydroindeno[1,2-b]pyrrole Heterocycle", Journal of Chemical Research(S), , 1996, p10 - 11
O.M. Walsh, M.J. Meegan, R.C. Prendergast and T.Al Nakib, Synthesis of 3-acetoxyazetidin-2-ones and 3-hydroxyazetidin-2-ones with antifungal and antibacterial activity, European Journal of Medicinal Chemistry, 31, 1996, p989 - 1000
A.C. O'Leary, A.D. Neary, C.M. Waldron and M.J. Meegan., Transformation of 3-Isopropenylazetidin-2-ones to 3-[1-(Hydroxymethyl)ethylidene}azetidin-2-ones, Journal of Chemical Research(S), , 1996, p368 - 369
Fiona M. Murphy and Mary J. Meegan, A New Synthesis of the 1,4-Dihydroindeno[1,2-b]pyrrole Heterocycle, Journal of Chemical Research (M), , 1996, p301 - 315
. A.C. O'Leary, A.D. Neary, C.M. Waldron and M.J. Meegan, Transformation of 3-Isopropenylazetidin-2-ones to 3-[1-(Hydroxymethyl)ethylidene}azetidin-2-ones,, Journal of Chemical Research (M), , 1996, p2162 - 2191
M. J. Meegan, T. Al Nakib and M. L. Burke., Synthesis of 1-[2-(Benzo[b]thiophen-3-yl)-2-benzyloxyethyl]-1H-imidazoles and 1-[2-(benzo[b]thiophen-3-yl)-2-benzyloxyethyl-1H-1,2-4-triazoles with Antifungal Activity., Journal of Chemical Research(M), 1994, p1042 - 1059
M. J. Meegan, S. J. Harris and A. M. Kinahan., Synthesis of 2-Azetidinones using Calixarenes as Phase Transfer Catalysts, Journal of Chemical Resarch(M), 1994, p1832 - 1845
E. P. Cooke, O. M. Walsh and M. J. Meegan., Reaction of Mixed Anhydrides with Imines:, Journal of Chemical Research(M), 1994, p2724 - 2759
E. P. Cooke, O. M. Walsh and M. J. Meegan., Reaction of Mixed Anhydrides with Imines:, J. Chem. Research(S), 1994, p470 - 471
M. J. Meegan, S. J. Harris and A. M. Kinahan., Synthesis of 2-Azetidinones using Calixarenes as Phase Transfer Catalysts., Journal of Chemical Resarch(S) , 1994, p324 - 325
M. J. Meegan, T. Al Nakib and M. L. Burke., Synthesis of 1-[2-(Benzo[b]thiophen-3-yl)-2-benzyloxyethyl]-1H-imidazoles and 1-[2-(benzo[b]thiophen-3-yl)-2-benzyloxyethyl-1H-1,2-4-triazoles with Antifungal Activity., Journal of Chemical Research(S), 1994, p170 - 171
M. J. Meegan, Ailish Looney, Louise Burke and T. Al Nakib., Synthesis and antifungal activity of some 2-aryl-3-hydroxymethylbenzo[b]thiophenes., European Journal of Medicinal Chemistry,, 27, (9), 1992, p971 - 976
C. Waldron and M. J. Meegan., 3-Vinyl-betalactams as intermediates for carbapenem antibiotics, Pharmaceutisch Weekblad Scientific Ed, 14, (5), 1992, p25 - 25
T. Al Nakib, M. Abu-Lisan, G. Al-Jahari and M. J. Meegan., Antimycotic Activity and Acute Toxicity of Benzopyranopyrans and Related Compounds., Medical Principles and Practice, 2, 1991, p222 - 227
M. J. Meegan, T. Al Nakib, Brendan Fullam, V. Bezjak and S. Rashid., Synthesis and antifungal activity of 2-amino-4-aryl-4H - 5H-[1] benzothiopyrano[4,3-b]pyran-3-carbonitriles and 2-alkoxy-4-aryl-5H[1]benzothiopyrano[4,3-b]pyridine-3-carbonitriles., European Journal of Medicinal Chemistry, 26, 1991, p221 - 230
M. J. Meegan, Bridget Fleming and Orla Walsh., Synthesis of Monocyclic beta-lactams by Solid Liquid Phase Transfer Reactions., Journal of Chemical Research (S) , 1991, p156 - 157
T. Al Nakib, V. Bezjak, M. J. Meegan and R. Chandy., Synthesis and antifungal activity of some 3-benzylidenechroman-4-ones, 3-benzylidenethiochroman-4-ones and 3-benzylidene-1-tetralones., European Jounal of Medicinal Chemistry , 25, 1990, p455 - 462
T. Al Nakib, N. J. Miller, S. Rashid and M. J. Meegan., An evaluation of the acute In vivo toxicity of benzylidenechroman-4-ones, 1-thiobenzylidenechroman-4-ones and benzylidenetetralones. , Drug and Chemical Toxicology, 13, 1990, p195 - 207
T. Al Nakib, V. Bezjak, S. Rashid, M. J. Meegan., Structure to Antimycotic Activity of Benzylidenechomanones against 6 Miconazole - Resistant Pathogenic Yeasts in vitro., Medical Principles and Practice, 2, 1990, p100 - 105
P. B. Deasy, M. P. Finan and M. J. Meegan., Preparation and characterization of lactic/glycolic acid polymers and copolymers., Journal of Microencapsulation, 6, (3), 1989, p369 - 378
D. V. Tyndall, J. P. Acton and M. J. Meegan., Arylation of 2,2-dimethyl-2H-1-benzopyrans with arylpalladium complexes: a new synthesis of the 4-aryl-2,2-dimethyl-2H-1-benzopyran (neoflavene) ring system., Proceedings of the Royal Irish Academy, 98B, 1989, p241 - 250
M. J. Meegan, D. V. Tyndall and E. T. MCarthy., A new synthesis of 4-phenylpyrido[3,2-b][1,4]benzothiazines(1-azaphenothiazines)., Journal of Chemical Research(M) , 1988, p1332 - 1352
D. V. Tyndall, T. Al Nakib and M. J. Meegan., A novel synthetic route to phenyl-substituted pyridines., Tetrahedron Letters , 28, 1988, p2703 - 2706
M. J. Meegan, D. V. Tyndall and E. T. MCarthy., A new synthesis of 4-phenylpyrido[3,2-b][1,4]benzothiazines(1-azaphenothiazines)., Journal of Chemical Research,(S), 1988, p145 - 145
M. J. Meegan., "The synthesis and antifungal activity of 6-hydroxy-11-thiopterocarpans, Journal of Pharmacy and Pharmacology, 38, 1986, p105 - 105
Furans and benzo derivatives, preparation and application in, Comprehensive heterocyclic chemistry, Oxford, Pergamon Press, 1984, pp657 - 712, [M. J. Meegan and D. M. X. Donnelly.]
A. R. Battersby, C. J. Fookes, E. McDonald, M. J. Meegan and H. Wurtziger., Biosynthesis of porphyrins and related macrocycles, Part 16., Journal of the Chemical Society Perkin Transactions 1, 1981, p2786 - 2799
D. M. X. Donnely, M. O'Sullivan, T. O'Criodan and M. J. Meegan., Dalbergia species Part XIII., Phytochemistry, 20, 1981, p1089 - 1092
H. Wagner, B. O'Donnell, D. M. X. Donnelly and M. J. Meegan., Structure of a new 4-Phenylbenzopyran-2-one from Pityrogramma calomelanos., Tetrahedron Letters, 1979, p4269 - 4273
A. R. Battersby, C. J. Fookes, E. McDonald and M. J. Meegan., Biosynthesis of Type III Porphyrins., Journal of the Chemical Society Chemical Communications , 1978, p185 - 186
P.J. Gunning, P. Kavanagh, M. J. Meegan and D. M. X. Donnelly., Reactions of 6a, 11a-dihydro-6H-benzofuro[3,2-c][1]benzopyrans., Journal of the Chemical Society Perkin Transactions 1, 1977, p691 - 694
Non-Peer-Reviewed Publications
Daniela Zisterer, Mary Meegan, Niamh O'Boyle, Miriam Carr, Lisa Greene and Thomas Greene, 'Combretastatin Derivatives and Uses Therefor', European Patent Office, EP2338877 A1, 2009
Thomas Greene, Tom McCabe and Mary J Meegan, The b-Lactam ring as a scaffold for combretastatin A-4 analogues , , Recent Advances in Synthesis and Chemical Biology, Royal College of Surgeons in Ireland, Dublin, December 15th, 2006,, 2006, ppP31-
Jason Horan and Mary J. Meegan, Synthesis and characterisation of 1,2,3,4-tetrahydroisoquinolines:, 2006All Ireland Schools of Pharmacy28th Research Seminar, Queens University Belfast, April 10-11, 2006, 2006, ppP24-
I.M. Barrett, M.J Meegan, D. M.Zisterer., Synthesis and Biochemistry of Some Novel Estrogen Receptor Antagonists , 2006All Ireland Schools of Pharmacy 28th Research Seminar , Queens University Belfast, April 10-11, 2006, 2006, pp12-
N.O. Keely, M.J. Meegan, Design, synthesis and evaluation of dual acting estrogen receptor conjugates, 2006All Ireland Schools of Pharmacy 28th Research Seminar, Queens University Belfast, April 10-11, 2006, 2006, pp40-
M.J.Meegan, , Design, synthesis and biochemical studies of novel estrogen receptor antagonists; , 15th Conference of GP2A, University of Bath, , Bath, UK, September 7-8, 2006,, 2006, ppI-4
Thomas F. Greene, Thomas McCabe, Mary J. Meegan., The â-Lactam Ring as a Scaffold for Combretastatin A-4 Analogues, 2006All Ireland Schools of Pharmacy, 28th Research Seminar, Queens University Belfast, April 10-11, 2006, 2006, ppP52-
Cormac A. O'Donohoe, Andrew S. Knox, and Mary J. Meegan, Antiproliferative and physiological stability studies , 2006All Ireland Schools of Pharmacy 28th Research Seminar, Queens University Belfast, April 10-11, 2006, 2006, ppP14-
Jason Horan and Mary J Meegan, Synthesis of a series of 1,2,3,4-tetrahydroisoquinoline analogues for use as selective estrogen receptor modulators, , Recent Advances in Synthesis and Chemical Biology, Royal College of Surgeons in Ireland, , Dublin, December 15th, 2006, ppP13-
Jason Horan and Mary J Meegan, Synthesis of a series of 1,2,3,4-tetrahydroisoquinoline analogues for use as selective estrogen receptor modulators,, 15th Conference of GP2A, University of Bath, Bath, UK, September 7-8, 2006, 2006, ppP19-
Niall O. Keely and Mary J Meegan,, Design and Synthesis and evaluation of dual acting estrogen receptor antagonist conjugates, Recent Advances in Synthesis and Chemical Biology, Royal College of Surgeons in Ireland, Dublin, December 15th, 2006,, 2006, ppP4-
Thomas Greene, Tom McCabe and Mary J Meegan, , The b- {Lactam ring as a scaffold for combretastatin A-4 analogues , 15th Conference of GP2A, University of Bath, , Bath, UK , September 7-8, 2006,, 2006, ppP16-
Niall O.Keely and Mary J Meegan, Design and Synthesis and evaluation of dual acting estrogen receptor antagonist conjugates, 15th Conference of GP2A, University of Bath,, Bath, UK, September 7-8, 2006, 2006, ppP23-
Georgia Golfis, Andrew J.S. Knox, Mary J. Meegan, , Charting Cancer Medicinal Chemistry Space, Recent Advances in Synthesis and Chemical Biology IV, University College Dublin , 2nd December 2005, 2nd December 2005, 2005, ppP39-
Niall O. Keely and Mary J. Meegan, Design, synthesis and biochemistry of dual acting estrogen receptor conjugates - synthesis and antiestrogenic effects in human breast cancer cells, Recent Advances in Synthesis and Chemical Biology IV , University College Dublin , 2nd December 2005, 2nd December 2005, 2005, ppP75-
Andrew Knox, Mary Meegan, Vlavimir Sobolev, Dermot Frost, David Lloyd, Development, refinement and validation of a novel vHTS protocol for ER alpha antagonists, Biomolecular Simulations - From Prediction to Practice: MGMS International Meeting 2005, Trinity College Dublin , 11-14 September 2005, 2005
Jason Horan and Mary J. Meegan , Synthesis of a series of 1,2,3,4 -Tetrahydroisoquinoline Analogues :, Recent Advances in Synthesis and Chemical Biology IV, University College Dublin , , 2nd December 2005, 2005, ppP67-
Claire M. Gorry, Andrew S. Knox, Cormac A. O'Donohoe and Mary J. Meegan, ANTIPROLIFERATIVE AND PHYSIOLOGICAL STABILTY STUDIES OF NOVEL 1,4-DIHYDROPYRIDINES, Recent Advances in Synthesis and Chemical Biology IV, University College Dublin ,, 2nd December 2005, 2005, ppP62-
Andrew J.S. Knox, Mary J. Meegan, Vladimir Sobolev, Dermot Frost, David G. Lloyd, Development, refinement and validation of a novel vHTS protocol for ER alpha antagonists, Recent Advances in Synthesis and Chemical Biology IV,, University College Dublin , 2nd December 2005, 2005, ppP60-
Thomas F. Greene, Mary J. Meegan., The â-Lactam Ring as a Scaffold for Combretastatin A-4 Analogues, Recent Advances in Synthesis and Chemical Biology IV, University College Dublin , , 2nd December 2005, 2005, ppP32-
Mary J. Meegan, D. M. Zisterer, Irene M. Barrett, Non-isomerisable Estrogen Receptor Modulators:Potential for the Treatment of Breast Cancer, Recent Advances in the Synthesis and Chemical Biology III, Centre for Synthesis and Chemical Biology, Trinity College Dublin, 13 December, 2004
A.S.Knox, M.J.Meegan, D.Frost, D.M.Zisterer and D.G.Lloyd, Identification of novel anticancer agents with "Forward-Reverse" virtual high throughput screening, Cancer Drug discovery. IBC's 9th Annual World Congress:Drug Discovery Technology, Boston, USA, August 8-13, 2004
Andrew S Knox, Mary J Meegan, Dermot Frost, Daniela M. Zisterer, David G. , Identification of anticancer agents with 'Forward-Reverse' virtual high throughput , 228th ACS meeting, PHILADELPHIA, 22-26-AUG-2004, 2004
Andrew Knox, Mary Meegan, Dermot Frost, David Lloyd, "Identification of novel anticancer agents with 'Forward-Reverse' virtual high throughput screening (Effect of Database pre-processing)", Young Modellers Forum, LONDON, 3-DEC-2004, 2004
Andrew Knox, Mary J.Meegan, Dermot Frost , James C. Sexton, David G. Lloyd, Validation of a new virtual high throughput screening protocol for estrogen receptor antagonists, Reaction Mechanisms VII, University College Dublin, 4-8 July, 2004
Irene M. Barrett and Mary J Meegan, Mechanism of Action of Non-isomerisable Estrogen Receptor Modulators, Reaction Mechanisms VII, University College Dublin, 4-8 July, 2004
Andrew Knox , Mary Meegan , Dermot Frost , David Lloyd, Ligand pre-processing in virtual screening - the impact of database preparation on hit retrieval, ECHEMINFO, ONLINE, 8-19-DEC-2004, 2004
Miriam Carr, Mary J. Meegan, D. M. Zisterer, Cytotoxic β-Lactams: synthesis and antiproliferative effects, Recent Advances in the Synthesis and Chemical Biology III, Centre for Synthesis and Chemical Biology, Trinity College Dublin, 13 December, 2004
JJ Keating, MJ Meegan and D Corrigan, Impurity profiling of PMK and PK, (key ketone precursors of the amphetamine derivatives MDMA and MBDB), synthesised via the Prilazhaev route, Proceedings of the twenty-fifth TCD/QUB annual joint research seminar, Trinity College Dublin, March, 2003, pp2 - 2
AS Knox, MJ Meegan, D Frost and JC Sexton, Development of a virtual high-throughput screening protocol for estrogen receptor antagonists, Proceedings of the twenty-fifth TCD/QUB annual joint research seminar, Trinity College Dublin, March, 2003, pp18 - 18
Helena M Smith, Andrew S Knox, Mary J Meegan, Timothy P O'Sullivan, and DM Zisterer, Synthesis and Biochemical evaluation of Novel Antiestrogens, Recent Advances in Synthesis and Chemical Biology II, Royal College of Surgeons in Ireland, December, 2003, pp58 - 58
Mary J Meegan, James J Keating and Desmond Corrigan, Impurity Profiling of PMK and PEK, (key ketone precursors of the amphetamine derivatives MDMA and MBDB), synthesised via the Prilazhaev route, Recent Advances in Synthesis and Chemical Biology II, Royal College of Surgeons in Ireland, December, 2003, pp55 - 55
Mary M O'Sullivan and Mary J Meegan, Investigation of a library of 1,2,3,4-tetrahydroisoquinolines and related compounds as dual inhibitors of monoamine oxidase and acetyl cholinesterase, Recent Advances in Synthesis and Chemical Biology II, Royal College of Surgeons in Ireland, December, 2003, pp59 - 59
Andrew S Knox, Mary J Meegan, Dermot Frost and James C Sexton, Validation and development of a virtual high-throughput screening protocol for estrogen receptor antagonists, Recent Advances in Synthesis and Chemical Biology II, Royal College of Surgeons in Ireland, December, 2003
Andrew S Knox, Mary J Meegan, Timothy P O'Sullivan, Helena M Smith and DM Zisterer, Synthesis, Computational Modelling and Biochemical Evaluation of Novel Antiestrogens, Conway Festival of Research, University College Dublin, September, 2003, pp69 - 69
Miriam Carr, Mary J Meegan, Helena Smith and DM Zisterer, Beta-lactam structure as a scaffold for non-isomerisable estrogen receptor modulators - synthesis, computational modelling and antiestrogenic effects, Recent Advances in Synthesis and Chemical Biology II, Royal College of Surgeons in Ireland, December, 2003, pp57 - 57
SG Butler and MJ Meegan, Strategies for the design and synthesis of novel selective serotonin reuptake inhibitors, Proceedings of the twenty-fifth TCD/QUB annual joint research seminar, Trinity College Dublin, March, 2003, pp19 - 19
M O'Sullivan and MJ Meegan, Investigation of a library of 1,2,3,4-tetrahydroisoquinolines and related compounds with monoamine oxidase inhibitory activity, Proceedings of the twenty-fifth TCD/QUB annual joint research seminar, Trinity College Dublin, March, 2003, pp8 - 8
JJ Keating, MJ Meegan, SG Butler, GG Shaw and D Corrigan, 6-Halo Derivatives of MDMA (Ecstasy) and MBDB: Synthesis and Pharmacological Activity, Recent Advances in Synthesis and Chemical Biology, University College Dublin, December, 2002, pp27 - 27
MT Breen and MJ Meegan, Novel monoamine oxidase inhibitors (MAOIs), Recent Advances in Synthesis and Chemical Biology, University College Dublin, December, 2002, pp39 - 39
AS Knox, MJ Meegan, TP O'Sullivan, HM Smith and DM Zisterer, Synthesis, Computational Modelling and Biological Evaluation of Novel Antiestrogens, Recent Advances in Synthesis and Chemical Biology, University College Dublin, December, 2002, pp54 - 54
MT Breen and MJ Meegan, Structure activity relationship study of novel monoamine oxidase inhibitors, Royal Society of Chemistry, Third International Meeting on Drugs from Natural Products, Trinity College Dublin, July, 2002, pp32 - 32
Niamh O'Boyle and Mary J. Meegan , Synthesis, Biochemical evaluation and molecular modelling studies of novel heterocyclic compounds, American Chemical Society 236th National meeting, Philadelphia, USA, 17-21 August 2008
Niamh O'Boyle and Mary J. Meegan, Synthesis and Biolchemical Evaluation of Heterocyclic Anti-Cancer Compounds , Recent Advances in Synthesis and Chemical Biology VII, University College Dublin, December12th, 2008, ppP60-
Yvonne McNamara, Suzanne Cloonan, D. Clive Williams and Mary J. Meegan,, Synthesis and Biochemical Evaluation of Novel Agents which Bind to the Serotonin Transporter (SERT) and Exhibit a Potential Chemotherapeutic Effect, Recent Advances in Synthesis and Chemical Biology VII, University College Dublin, December12th, 2008, ppP37-
Niall O. Keely and Mary J Meegan, Design, Synthesis and Biochemical Evaluation of Novel Estrogen receptor conjugates for the treatment of hormone dependent breast cancer, American Chemical Society 236th National meeting, Philadelphia, USA, 17-21 August 2008
Wei Shi, Cormac O'Donohoe and Mary J. Meegan , Synthesis and in vitro testing of Pyrazole 1, 4-Dihydropyridines for their anti-proliferative properties, Recent Advances in Synthesis and Chemical Biology VII, University College Dublin, December12th, 2008, ppP55-
Research Expertise
Description
My research interests lie in Pharmaceutical Chemistry in the rational design of new medicines, specifically in the design of highly potent and selective estrogen receptor modulators (SERMs) which may be utilised in the treatment of breast cancer and osteoporosis. Extensive molecular modelling analysis of the specific interactions between drugs such as tamoxifen and raloxifene and models of the protein target (the Estrogen Receptor) has led to the design and synthesis of novel structurally modified estrogen receptor modulators with altered selectivity and affinity for the protein receptor. Ongoing research is examining the relationship between structure and antiproliferative activity of these products against MCF-7 breast cancer cells, and may lead to a better understanding of the specific structural requirements for estrogen receptor agonist and antagonist activity. This research work is carried out in collaboration with Dr. D. Zisterer and Dr. D. Lloyd in the Department of Biochemistry, Trinity College Dublin. Related research interests include the investigation of the mechanism of action of novel cytotoxic heterocycles against breast cancer cell lines (both ER+ and ER-)and the development of virtual high throughput screening computational methodologies for the identification of new anticancer molecular scaffolds. In addition, we have extensive expertise in the area of impurity profiling of amphetamines and related ecstasy type drugs of abuse and also have established current research projects involving the design and evaluation of novel selective serotonin reuptake inhibitors.Projects
- Title
- Development of an in silico high-throughput screening system for the estrogen receptor
- Summary
- Before the advent of rational drug design (RDD), new drug candidates were screened randomly and the success rates were extremely low (about 1 in 15 000) thus delaying the provision of new therapeutics. The development of RDD approaches has given researchers the power to design candidate drugs based on the physico-chemical properties of their targets. The output from the human genome project and the technologies of proteomics and structural genomics are now furnishing validated targets for varied disease states. In this project we have developed a suite of computational drug design programs optimised to carry out high throughput in silico screening of candidate compounds on highly parallel computing systems using X-ray crystal or homology models of biological receptors for specific disease states. Initially we have focussed on the development of computational docking algorithms to fit candidate ligands to the estrogen receptors to facilitate our research in the development of therapeutics for use in breast cancer treatment. The efficacy of fit arising from these docking routines is complimented through parallel wet biochemical experimental evaluation of binding affinities for ligands in cloned estrogen receptors using commercially available assay kits. This experimental data has been used to validate the in silico methodology and to provide refinement parameters in the development and optimisation of scoring algorithms. These tools will be applicable in the design of ligands for any pathogenic process wherein a target protein structure is known or may be determined, thus shortening R&D times for the provision of new therapeutics
- Funding Agency
- Health Research Board
- Date From
- September 2002
- Date To
- September 2005
Recognition
Representations
Guest Editor of Current Topics in Medicinal Chemistry
Awards and Honours
Royal Commission 1851 Overseas Postdoctoral Fellowship
Hugh Ryan Gold Medal in Chemistry, University College Dublin
Memberships
Member of the Royal Society of Chemistry
Member of the American Chemical Society
Member of the Society of the Chemical Industry Chartered Chemist